Effect of Caffeine-Containing Beverages on Physicochemical and Release Properties of Halofantrine

Authors

  • Chinedum Peace BABALOLA

  • Chinedum Peace BABALOLA

Keywords:

caffeine, halofantrine, physicochemical interaction

Abstract

Halofantrine (Hf) is a poorly water-soluble drug for treating malaria in endemic areas like tropical Africa, where caffeine-containing products are habitually consumed. Previous reports showed that caffeine increased the aqueous solubility of Hf at room temperature over 3 days. The aim of this study was to determine the effect of caffeine and caffeine-containing beverages on dissolution and solubility of Hf and to investigate any possible interactions. The aqueous solubility and dissolution of Hf alone and in the presence of caffeine was investigated at pH 1.3, 5.9 and 7.4 using standard methods. The solubility of Hf in the presence of aqueous extracts of cocoa, coffee, black tea and green tea at pH 5.9 was also investigated. In 1 hour, caffeine markedly increased the aqueous solubility of Hf at pH 1.3, 5.9 and 7.4. Caffeine and caffeine-containing beverages markedly increased the aqueous solubility of Hf by between 100-to more than 1600-fold, with a 1672-fold increase by caffeine (from 76.6 ±7.8 ng/mL to128.2 ± 4.5 mg/mL) at pH 5.9. The dissolution of Hf tablets at pH 1.3, 5.9 and 7.4 showed the respective amounts released as 3.57 ± 0.09, 0.95 ± 0.19 and 0.260 ± 0.043 mg, but introduction of caffeine increased these values to 9.51 ± 0.23, 3.70 ± 0.12 and 0.52 ± 0.10 mg respectively, representing 3-fold, 4-fold and 2-fold respectively.

How to Cite

Effect of Caffeine-Containing Beverages on Physicochemical and Release Properties of Halofantrine. (2014). Global Journal of Medical Research, 14(B1), 5-10. https://medicalresearchjournal.org/index.php/GJMR/article/view/517

References

C Babalola, A Adegoke, M Ogunjimi, M Osimosu (2003) Determination of physicochemical properties of halofantrine. 32(4), 357-359.

L Schmidt, Ruth Crosby, Jane Rasco, Dennis Vaughan (1978) Antimalarial Activities of Various 9-Phenanthrenemethanols with Special Attention to WR-122,455 and WR-171,669. 14(3), 292-314.

G Childs, C Lambros, J Notsch, C Pamplin, D Davidson, A Ager (1984) Comparison ofin vitroandin vivoantimalarial activities of g-phenanthrenecarbinols. 78(1), 13-20.

W Watkins, J Oloo, J Lury, M Mosoba, D Kariuki, M Mjomba, D Koech, H Gilles (1988) Efficacy of multiple-dose halofantrine in treatment of chloroquine-resistant falciparum malaria in children in Kenya. 30(8605), 247-250.

F Ter Kuile, G Dolan, F Nosten, M Edstein, C Luxemburger, L Phaipun, T Chongsuphajaisiddhi, H Webster, N White (1993) Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. 24(8852), 1044-1049.

E Boudreau, L Pang, K Dixon, H Webster, K Pavanand, L Tosingha, P Somutsakorn, C Canfield (1988) Malaria: treatment efficacy of halofantrine (WR 171,669) in initial field trials in Thailand. 66(2), 227-235.

H Bryson, K Goa (1992) Halofantrine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic potential. 43(2), 236-258.

K Milton, G Edwards, S Ward, M Orme, A Breckenridge (1989) Pharmacokinetics of halofantrine in man: effects of food and dose size.. 28(1), 71-77.

Sylvester Aideloje, Cyprian Onyeji, Nicholas Ugwu (1998) Altered pharmacokinetics of halofantrine by an antacid, magnesium carbonate. 46(3), 299-303.

P Bassi, C Onyeji, O Ukponmwan (2004) Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers. 58(1), 52-55.

Lee-Yong Lim, Mei-Lin Go (2000) Caffeine and nicotinamide enhances the aqueous solubility of the antimalarial agent halofantrine. 10(1), 17-28.

Y Kolade, C Babalola, A Olaniyi, G Scriba (2008) Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine. 64(1), 77-81.

Y Kolade, C Babalola, G Scriba (2006) Analysis of the antimalarial drug halofantrine and its major metabolite N-desbutylhalofantrine in human plasma by high performance liquid chromatography. 41(1), 315-319.

T Tanaka, A Okayama, S Seguchi, M Ohhashi, S Tahara, M Tamaki (2000) Health Effects and Risks of Caffeine, Theobromine and Theophylline. 34, 357-382.

T Cosgriff, E Boudreau, C Pamplin, E Doberstyn, R Desjardins, C Canfield (1982) Evaluation of the antimalarial activity of the phenanthrenemethanol halofantrine (WR 171,669). 31(6), 1075-1079.

W Colwell, V Brown, P Christie, J Lange, C Reece, K Yamamoto, D Henry (1972) Antimalarial arylaminopropanols. 15(7), 771-775.

E Monlun, O Pillet, J Cochard, Favarel Garrigues, J, Le Bras, M (1993) Prolonged QT interval with halofantrine. 341(8859), 1541-1542.

M Fawzi, E Davison, M Tute (1980) Rationalization of drug complexation in aqueous solution by use of Hückel frontier molecular orbitals. 69(1), 104-106.

Alaa Rasool, Anwar Hussain, Lewis Dittert (1991) Solubility Enhancement of Some Water-Insoluble Drugs in the Presence of Nicotinamide and Related Compounds. 80(4), 387-393.

Effect of Caffeine-Containing Beverages on Physicochemical and Release Properties of Halofantrine

Published

2014-03-20

How to Cite

Effect of Caffeine-Containing Beverages on Physicochemical and Release Properties of Halofantrine. (2014). Global Journal of Medical Research, 14(B1), 5-10. https://medicalresearchjournal.org/index.php/GJMR/article/view/517